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Abstract
IMPORTANCE The chronic receipt of angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) has been assumed to exacerbate complications associated with
COVID-19 and produce worse clinical outcomes.
OBJECTIVE To conduct an updated and comprehensive systematic review and meta-analysis
comparing mortality and severe adverse events (AEs) associated with receipt vs nonreceipt of ACEIs
or ARBs among patients with COVID-19.
DATA SOURCES PubMed and Embase databases were systematically searched from December 31,
2019, until September 1, 2020.
STUDY SELECTION The meta-analysis included any study design, with the exception of narrative
reviews or opinion-based articles, in which COVID-19 was diagnosed through laboratory or
radiological test results and in which clinical outcomes (unadjusted or adjusted) associated with
COVID-19 were assessed among adult patients (18 years) receiving ACEIs or ARBs.
DATA EXTRACTION AND SYNTHESIS Three authors independently extracted data on mortality
and severe AEs associated with COVID-19. Severe AEs were defined as intensive care unit admission
or the need for assisted ventilation. For each outcome, a random-effects model was used to compare
the odds ratio (OR) between patients receiving ACEIs or ARBs vs those not receiving ACEIs or ARBs.
MAIN OUTCOMES AND MEASURES Unadjusted and adjusted ORs for mortality and severe AEs
associated with COVID-19.
RESULTS A total of 1788 records from the PubMed and Embase databases were identified; after
removal of duplicates, 1664 records were screened, and 71 articles underwent full-text evaluation.
Clinical data were pooled from 52 eligible studies (40 cohort studies, 6 case series, 4 case-control
studies, 1 randomized clinical trial, and 1 cross-sectional study) enrolling 101 949 total patients, of
whom 26 545 (26.0%) were receiving ACEIs or ARBs. When adjusted for covariates, significant
reductions in the risk of death (adjusted OR [aOR], 0.57; 95% CI, 0.43-0.76; P < .001) and severe AEs
(aOR, 0.68; 95% CI, 0.53-0.88; P < .001) were found. Unadjusted and adjusted analyses of a
subgroup of patients with hypertension indicated decreases in the risk of death (unadjusted OR,
0.66 [95% CI, 0.49-0.91]; P = .01; aOR, 0.51 [95% CI, 0.32-0.84]; P = .008) and severe AEs
(unadjusted OR, 0.70 [95% CI, 0.54-0.91]; P = .007; aOR, 0.55 [95% CI, 0.36-0.85]; P = .007).
(continued)
Key Points
Question Is the receipt of angiotensin-
converting enzyme inhibitors (ACEIs)
or angiotensin receptor blockers (ARBs)
associated with worse clinical outcomes
among patients with COVID-19?
Findings In this systematic review and
meta-analysis of 52 studies that
evaluated clinical outcomes among
101 949 total patients with COVID-19
who did and did not receive ACEIs or
ARBs, a significantly lower risk of
multivariable-adjusted mortality and
severe adverse events was found among
patients who received ACEIs or ARBs
compared with patients who did not. A
subgroup analysis of patients with
hypertension indicated significant
decreases in mortality and severe
adverse events among patients
receiving ACEIs or ARBs in both
unadjusted and adjusted analyses.
Meaning The study’s findings suggest
that ACEIs and ARBs may be associated
with protective benefits for patients
with COVID-19 and that patients may
continue receiving ACEIs and ARBs for
the treatment of any condition without
an increased risk of worse outcomes
unless specifically advised to avoid them
by treating clinicians.
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Abstract (continued)
CONCLUSIONS AND RELEVANCE In this systematic review and meta-analysis, receipt of ACEIs or
ARBs was not associated with a higher risk of multivariable-adjusted mortality and severe AEs among
patients with COVID-19 who had either hypertension or multiple comorbidities, supporting the
recommendations of medical societies. On the contrary, ACEIs and ARBs may be associated with
protective benefits, particularly among patients with hypertension. Future randomized clinical trials
are warranted to establish causality.
JAMA Network Open. 2021;4(3):e213594. doi:10.1001/jamanetworkopen.2021.3594
Introduction
Coronavirus disease 2019 (COVID-19), a rapidly evolving pandemic infecting more than 93 million
people worldwide to date,1 is associated with worse clinical outcomes in patients with existing
cardiovascular diseases, including hypertension and diabetes.2,3 Renin-angiotensin-aldosterone
system (RAAS) inhibitors, specifically angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs), which are frequently used for the treatment of cardiovascular
conditions, are subjects of debate because angiotensin-converting enzyme 2 acts as a binding site
for the virus to gain cellular entry.4 This debate has elicited several theories suggesting that the
chronic receipt of RAAS inhibitors may exacerbate COVID-19 and produce worse outcomes.4
Several observational studies have since evaluated the association of ACEIs and ARBs (ACEIs/
ARBs) with clinical outcomes in patients with COVID-19. Although a few studies have reported an
increased risk of severe disease,5,6 most have found no association7,8 or even beneficial associations
with the receipt of these drugs.9,10 A previous meta-analysis11 that examined 16 studies with 28 000
total patients reported no significant association between the receipt of ACEIs/ARBs and mortality
or severe adverse events (AEs) among individuals with multiple comorbidities (OR, 0.67; 95% CI,
0.44-1.03; P = .07) and a significant association between ACEIs/ARBs and protective benefits among
individuals with hypertension (OR, 0.67; 95% CI, 0.50-0.91; P = .01). Since the publication of that
meta-analysis, more original studies have been published, allowing increased statistical power to
further investigate specific subgroups.
Given the increasing number of COVID-19 cases and an evolving second wave of infections, it is
important to summarize the data thus far to provide an updated perspective and an understanding
of the association between ACEIs/ARBs and clinical COVID-19 outcomes. The inclusion of more
studies and patients will allow the identification of more accurate associations with smaller CIs,
producing findings that are more likely to represent true associations. In addition, the inclusion of
only peer-reviewed studies will reinforce the conclusions. Findings from the present meta-analysis
will be relevant for the clinical management of millions of patients receiving these drugs worldwide.12
Methods
Study Selection
The PubMed and Embase databases were systematically searched from December 31, 2019, until
September 1, 2020, for studies published in English. Terms such as angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers, coronavirus disease 2019, and SARS-COV-2 were used for a
comprehensive search. Additional details about the search strategy are available in eMethods in the
Supplement. The references of retrieved articles were manually screened for relevant studies to
expand the search. This study followed the Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) reporting guideline.
All studies identified in our search were screened by 3 authors (R.B., M.D., and V.T.) using article
titles and abstracts. Duplicate studies and multiple reports using the same data were removed. Any
JAMA Network Open | Cardiology Renin-Angiotensin-Aldosterone System Inhibitors in Patients With COVID-19
JAMA Network Open. 2021;4(3):e213594. doi:10.1001/jamanetworkopen.2021.3594 (Reprinted) March 31, 2021 2/18
Downloaded From: https://jamanetwork.com/ by a University of East Anglia Library User  on 04/02/2021
article identified as having the potential to fulfill our inclusion criteria underwent full-text evaluation.
We included studies meeting the following criteria: (1) any study design, with the exception of
narrative reviews and opinion-based articles; (2) adult (18 years) study population; (3) participants
with COVID-19 diagnosed through laboratory or radiological test results; and (4) assessment of
clinical or mortality outcomes (unadjusted or adjusted) among patients receiving ACEIs/ARBs. The
mortality and clinical severity data of patients receiving ACEIs/ARBs were compared with those of
patients not receiving ACEIs/ARBs.
Data Extraction and Quality Assessment
Three authors (R.B., V.T., and M.D.) independently extracted relevant data from included studies
using a standardized extraction form. Any disagreements were resolved by discussion. The data
extracted included the type of study, the number and characteristics of patients receiving ACEIs/
ARBs, and mortality and severe AEs associated with COVID-19.
Severe AEs were defined as intensive care unit admission or the need for invasive or
noninvasive ventilation. Studies reporting severe AEs based on information from the Chinese Center
for Disease Control and Prevention13 were included. To avoid double-counting of patients in studies
reporting multiple severe AE outcomes, we included the outcome with the largest number of
patients in our analyses. For instances in which distinct data for ACEIs/ARBs were available, an
aggregate was used given the small likelihood of combined receipt of both drugs.
The Newcastle-Ottawa Scale,14 a 9-point measure assessing the quality of cohort studies and
case-control studies or case series, was used to evaluate the observational studies included. The
Cochrane Risk of Bias 2 tool was used to assess the risk of bias in randomized clinical trials.15
Statistical Analysis
For each outcome, a random-effects model was used to compare the odds ratios (ORs) and 95% CIs
between patients who did and did not receive ACEIs/ARBs using Review Manager software, version
5.3 (Nordic Cochrane Center), and OpenMeta[Analyst] software, version 10.12 (Center for Evidence
Synthesis, Brown University).16 For studies reporting hazard ratios (HRs), those HRs were converted
to ORs using methodology defined in the Cochrane Handbook for Systematic Reviews of
Interventions.17 Results from studies were grouped according to a prespecified variable (patients with
hypertension [hypertension subgroup] vs patients with multiple mixed comorbidities [mixed
subgroup]), and a series of subgroup analyses were performed. We also conducted a sensitivity
analysis, in which studies reporting HRs (which were converted to ORs) were excluded to assess the
robustness of results.
Statistical heterogeneity was assessed using the I2 statistic. Potential publication bias was
assessed using funnel plots. The statistical significance threshold was P < .05.
Results
Our search identified 1788 records from the PubMed and Embase databases; after removal of
duplicates, 1664 records were screened, and 71 articles underwent full-text evaluation (eFigure 1 in
the Supplement). Of those, 52 studies (40 cohort studies, 6 case series, 4 case-control studies, 1
randomized clinical trial, and 1 cross-sectional study) with 101 949 total participants met inclusion
criteria and were included in the meta-analysis. The cohorts and methodological characteristics of
the studies are described in the Table. Ten studies were ranked as having moderate quality and 41
studies were ranked as having high quality based on the Newcastle-Ottawa Scale (eTable in the
Supplement). Funnel plots indicated no substantial publication biases (eFigure 2 and eFigure 3 in the
Supplement).
Most studies included in the meta-analysis were retrospective20,21,33,44 or
observational4,6,26,37,61-63 and were conducted in China,4,8,10,23-25,28,31,32,35,39,41,45,48,55,58-60,62,64-66
Europe,5,7,9,18,19,22,30,34,40,43,46,47,51-53,56,57 or North America.6,20,49,50,54 Two studies22,38 included a
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subgroup of patients receiving ACEIs/ARBs that were explicitly discontinued during hospital
admission. The results from this subgroup of patients were included in the group of patients
receiving ACEIs/ARBs and compared with those not receiving ACEIs/ARBs. In studies in which both
multivariate and propensity-matched scores were reported,28,42,61 data from the multivariate
analyses were used. A total of 26 545 of 101 949 patients (26.0%) overall and 4813 of 11 696 patients
(41.2%) in the hypertension subgroup were receiving ACEIs/ARBs (Table).
Mortality
A total of 41 studies (69 577 total participants) that compared mortality rates of patients receiving vs
not receiving ACEIs/ARBs were included in the meta-analysis. Overall, the results of the pooled
unadjusted meta-analysis indicated no increases in the risk of death among those who received
ACEIs/ARBs (unadjusted OR, 1.05; 95% CI, 0.86-1.29; P = .61; I2 = 85.0%) compared with those who
did not (Figure 1). The subgroup analysis revealed significant reductions in mortality among patients
in the hypertension subgroup who were receiving ACEIs/ARBs (unadjusted OR, 0.66; 95% CI,
0.49-0.91; P = .01). In contrast, the mixed subgroup comprising patients with multiple comorbidities
indicated significant increases in mortality among those receiving ACEIs/ARBs (unadjusted OR, 1.46;
95% CI, 1.15-1.85; P = .002)
However, a pooled analysis of 17 studies (17 392 total participants) using an adjusted analysis of
mortality found reductions in the risk of death among patients receiving vs not receiving ACEIs/
ARBs (adjusted OR [aOR], 0.57; 95% CI, 0.43-0.76; P < .001; I2 = 54.0%) (Figure 2). A significant
decrease in the risk of death was observed in both subgroups (for the hypertension subgroup, aOR,
0.51 [95% CI, 0.32-0.84]; P = .008; for the mixed subgroup, aOR, 0.64 [95% CI,
0.46-0.88]; P = .006).
Severe Adverse Events
Unadjusted values for severe AEs were reported in 48 studies that included a total of 98 985
participants. A pooled analysis found comparable results among patients who did and did not receive
ACEIs/ARBs (unadjusted OR, 1.11; 95% CI, 0.95-1.31; P = .20; I2 = 86.0%) (Figure 3). Notably, the 26
studies including a hypertension subgroup (unadjusted OR, 0.70; 95% CI, 0.54-0.91; P = .007) and
the 33 studies including a mixed subgroup (unadjusted OR, 1.50; 95% CI, 1.25-1.81; P < .001) reported
statistically significant results.
A total of 23 studies (23 129 total participants) reported an adjusted risk of severe AEs
associated with the receipt of ACEIs/ARBs in a COVID-19 cohort. The adjusted covariates for each
study are listed in the Table. A significant decrease in severe AEs was found in patients who received
ACEIs/ARBs compared with those who did not (aOR, 0.68; 95% CI, 0.53-0.88; P = .003; I2 = 67.0%)
(Figure 4). This reduced risk remained significant among the hypertension subgroup in 12 studies
(aOR, 0.55; 95% CI, 0.36-0.85; P = .007). However, in the mixed subgroup, the decreased risk was
not statistically significant (OR, 0.79; 95% CI, 0.59-1.07; P = .12). A sensitivity analysis that excluded
studies reporting HRs indicated statistically significant results for mortality but nonsignificant results
for severe AEs (eFigure 4 and eFigure 5 in the Supplement). Subgroup analyses of studies of
moderate quality (OR, 0.36; 95% CI, 0.25-0.51; P < .001) and high quality (OR, 0.78; 95% CI, 0.60-
1.00; P = .05) indicated reduced risk of adjusted severe AEs among both hypertension and mixed
subgroups (eFigure 6 in the Supplement).
Discussion
The results of this systematic review and meta-analysis of 52 studies with 101 949 total patients
indicated a significant association between the receipt of ACEIs/ARBs and reductions in mortality and
severe AEs among patients in the hypertension subgroup. In the mixed subgroup of patients with
multiple comorbidities, this association was observed only when the analysis was adjusted for
significant covariates.
JAMA Network Open | Cardiology Renin-Angiotensin-Aldosterone System Inhibitors in Patients With COVID-19
JAMA Network Open. 2021;4(3):e213594. doi:10.1001/jamanetworkopen.2021.3594 (Reprinted) March 31, 2021 9/18
Downloaded From: https://jamanetwork.com/ by a University of East Anglia Library User  on 04/02/2021
















0.62 5 2 6Amat-Santos et al,18 2020 1.33 (0.11-15.70)
0.71 78 5 512Bae et al,20 2020 1.32 (0.15-11.42)
4.1106 399 182 801Bean et al,21 2020 1.23 (0.93-1.62)
3.539 173 39 224Cannata et al,22 2020 1.38 (0.84-2.27)
4.2181 895 297 3585Fosbol et al,27 2020 2.81 (2.29-3.43)
2.17 19 36 168Guo et al,31 2020 2.14 (0.79-5.83)
1.75 13 21 90Hwang et al,33 2020 2.05 (0.61-6.95)
4.0106 655 82 936Iaccarino et al,34 2020 2.01 (1.48-2.73)
3.662 157 85 167Jung et al,35 2021 0.63 (0.41-0.98)
3.633 377 51 1577Jung et al,36 2020 2.87 (1.82-4.52)
3.017 96 30 172Liabeuf et al,40 2020 1.02 (0.53-1.96)
2.811 210 27 755Lopez-Otero et al,42 2020 1.49 (0.73-3.06)
2.68 211 34 1494Mehta et al,6 2020 1.69 (0.77-3.71)
3.765 192 80 212Mostaza et al,46 2020 0.84 (0.56-1.27)
2.110 44 9 105Oussalah et al,47 2020 3.14 (1.18-8.37)
4.1108 818 109 1835Rossi  et al,51 2020 2.41 (1.82-3.19)
3.638 207 48 324Shah et al,54 2020 1.29 (0.81-2.06)
4.43146 9522 8059 33 404Trifiro et al,57 2020 1.55 (1.48-1.63)
4.170 906 272 1812Zhou et al,10 2020 0.47 (0.36-0.62)
Heterogeneity: Τ2 = 0.19; χ2 = 156.09; df = 18; P <.001; I 2 = 88.0% 
58.6Subtotal 4015 14 977 9468 48 179 1.46 (1.15-1.85)
Test for overall effect: z = 3.07; P =.002
Hypertension subgroup 
2.321 68 13 28Conversano et al,19 2020 0.52 (0.21-1.27)
3.487 450 22 93Bravi et al,7 2020 0.77 (0.45-1.32)
3.112 355 95 827Chen et al,23 2020 0.27 (0.15-0.50)
1.64 32 10 39Chen et al,25 2020 0.41 (0.12-1.48)
2.615 82 18 51Felice et al,9 2020 0.41 (0.18-0.92)
1.94 183 19 527Gao et al,28 2020 0.60 (0.20-1.78)
0.41 65 0 84Hu et al,64 2020 3.93 (0.16-98.07)
1.85 27 14 61Khan et al,37 2020 0.76 (0.24-2.39)
3.858 335 62 279Lam et al,38 2020 0.73 (0.49-1.09)
3.321 115 56 247Li et al,39 2020 0.76 (0.44-1.33)
0.40 20 3 30Huang et al,32 2020 0.19 (0.01-3.92)
0.92 21 3 18Matsuzawa et al,44 2020 0.53 (0.08-3.56)
0.30 17 1 25Meng et al,45 2020 0.47 (0.02-12.14)
1.94 41 63 241Pan et al,48 2020 0.31 (0.10-0.89)
4.1130 413 254 953Richardson et al,50 2020 1.26 (0.98-1.63)
1.17 45 2 17Sardu et al,52 2020 1.38 (0.26-7.42)
1.831 74 4 39Selcuk et al,5 2020 6.31 (2.03-19.58)
1.77 104 5 52Senkal et al,53 2020 0.68 (0.20-2.25)
0.40 31 11 69Tan et al,55 2020 0.08 (0.00-1.42)
2.411 40 21 61Xu et al,58 2020 0.72 (0.30-1.73)
1.22 43 11 83Yang et al,59 2020 0.32 (0.07-1.51)
Heterogeneity: Τ2 = 0.24; χ2 = 52.51; df = 21; P <.001; I 2 = 60.0% 
1.0Zhou et al,8 2020 2 15 5 21 0.49 (0.08-2.97)
41.4
100
Subtotal 424 2576 692 3845 0.66 (0.49-0.91)
4439 17 553 10 160 52 024 1.05 (0.86-1.29)
Test for overall effect: z = 0.24; P =.01
Total
Heterogeneity: Τ2 = 0.23; χ2 = 269.12; df = 40; P <.001; I 2 = 85.0% 
Test for overall effect: z = 0.52; P =.61
Test for subgroup differences: χ2 = 15.27; df = 1; P <.001; I 2 = 93.5% 
Subgroup analysis of mortality in 41 studies of patients who did and did not receive ACEIs or ARBs. A total of 19 studies included a mixed subgroup (a sample population with multiple
mixed comorbidities), and 22 studies included a hypertension subgroup (a sample population with hypertension). Diamonds represent 95% CIs for subtotal and total ORs. ACEI
indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; and OR, odds ratio.
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Our results are consistent with those of another meta-analysis67 comprising 18 studies and
17 311 patients with hypertension. This previous meta-analysis reported a lower risk (risk ratio, 0.84;
95% CI, 0.73-0.95; P = .007) of the composite outcome (death, intensive care unit admission,
mechanical ventilation, and progression to severe or critical pneumonia) among patients receiving
ACEIs/ARBs. The present meta-analysis extends this finding to patients with multiple mixed
comorbidities, suggesting that ACEIs/ARBs may have a substantial protective role in COVID-19
outcomes across all patient groups.
Notably, the protective implications of ACEIs/ARBs in the mixed subgroup were observed only
after adjustments to potential and important confounders, such as age and comorbidities. This
finding suggests that comorbidities may have an important role in COVID-19 clinical outcomes and
that ACEIs/ARBs might be associated with further improvements in potential outcomes. In a large
retrospective cohort study by Fosbol et al27 that included 4480 patients with COVID-19, an
unadjusted analysis indicated worse outcomes among those who received ACEIs/ARBs. However,
after multivariate adjustments, this finding was no longer statistically significant. Similar results were
observed in multiple small retrospective cohort studies.29,36,42,54 It is worth noting that most studies
included in the meta-analyses were retrospective and observational; with these study designs,
unmeasured confounding factors and potential biases are inevitable. In addition, patients receiving
ACEIs/ARBs are more likely to have heart failure, cardiovascular disease, hypertension, and
comorbidities, which are associated with an increased risk of death among patients with COVID-19.3
Therefore, it is necessary to adjust for these confounders when evaluating the protective benefits
of ACEIs/ARBs for mortality and severe AEs.
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Heterogeneity: Τ2 = 0.09; χ2 = 13.26; df = 6; P =.04; I 2 = 55.0% 
57.5
100
Subtotal NA NA 0.64 (0.46-0.88)
NA NA 0.57 (0.43-0.76)
Test for overall effect: z = 2.73; P =.006
Total
Heterogeneity: Τ2 = 0.14; χ2 = 32.74; df = 15; P =.005; I 2 = 54.0% 
Test for overall effect: z = 3.82; P =.001
Test for subgroup differences: χ2 = 0.51; df = 1; P =.48; I 2 = 0% 
Subgroup analysis of adjusted mortality in 16 studies
of patients who did and did not receive ACEIs or ARBs.
A total of 7 studies included a mixed subgroup (a
sample population with multiple mixed comorbidities),
and 9 studies included a hypertension subgroup (a
sample population with hypertension). Diamonds
represent 95% CIs for subtotal and total ORs. ACEI
indicates angiotensin-converting enzyme inhibitor;
ARB, angiotensin receptor blocker; and OR, odds ratio.
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0.42 5 2 6Amat-Santos et al,18 2020 1.33 (0.11-15.70)
0.51 78 5 512Bae et al,20 2020 1.32 (0.15-11.42)
3.7127 399 288 801Bean et al,21 2020 0.83 (0.64-1.07)
2.939 173 39 224Cannata et al,22 2020 1.38 (0.84-2.27)
3.8181 895 297 3585Fosbol et al,27 2020 2.81 (2.29-3.43)
4.0420 4281 866 15 205Hippisley-Cox et al,26 2020 1.80 (1.59-2.03)
2.213 49 35 198Gormez et al,29 2020 1.68 (0.81-3.50)
1.25 13 21 90Hwang et al,33 2020 2.05 (0.61-6.95)
3.5106 655 82 936Iaccarino et al,34 2020 2.01 (1.48-2.73)
3.162 157 85 167Jung et al,35 2021 0.63 (0.41-0.98)
3.133 377 51 1577Jung et al,36 2020 2.87 (1.82-4.52)
1.67 19 36 168Guo et al,31 2020 2.14 (0.79-5.83)
2.952 96 64 172Liabeuf et al,40 2020 1.99 (1.20-3.31)
2.211 210 27 755Lopez-Otero et al,42 2020 1.49 (0.73-3.06)
3.9364 2896 253 3376Mancia et al,43 2020 1.77 (1.50-2.10)
3.265 192 80 212Mostaza et al,46 2020 0.84 (0.56-1.27)
2.18 211 34 1494Mehta et al,6 2020 1.69 (0.77-3.71)
1.610 44 9 105Oussalah et al,47 2020 3.14 (1.18-8.37)
3.6108 818 109 1835Rossi et al,51 2020 2.41 (1.82-3.19)
3.038 207 48 324Shah et al,54 2020 1.29 (0.81-2.06)
4.03146 9522 8059 33 404Trifiro et al,57 2020 1.55 (1.48-1.63)
3.670 906 272 1812Zhou et al,10 2020 0.47 (0.36-0.62)
Heterogeneity: Τ2 = 0.12; χ2 = 183.53; df = 21; P <.001; I 2 = 89.0% 
60.1Subtotal 4868 22 203 10 762 66 958 1.50 (1.25-1.81)
Test for overall effect: z = 4.34; P <.001
Hypertension subgroup 
1.821 68 13 28Conversano et al,19 2020 0.52 (0.21-1.27)
2.887 450 22 93Bravi et al,7 2020 0.77 (0.45-1.32)
2.512 355 95 827Chen et al,23 2020 0.27 (0.15-0.50)
1.24 32 10 39Chen et al,25 2020 0.41 (0.12-1.48)
2.015 82 18 51Felice et al,9 2020 0.41 (0.18-0.92)
0.92 33 23 80Feng et al,4 2020 0.16 (0.04-0.72)
1.44 183 19 527Gao et al,28 2020 0.60 (0.20-1.78)
0.30 20 3 30Huang et al,32 2020 0.19 (0.01-3.92)
1.35 27 14 61Khan et al,37 2020 0.76 (0.24-2.39)
3.258 335 62 279Lam et al,38 2020 0.73 (0.49-1.09)
0.21 65 0 84Hu et al,64 2020 3.93 (0.16-98.07)
2.721 115 56 247Li et al,39 2020 0.76 (0.44-1.33)
0.55 74 1 83Liu et al,41 2021 5.94 (0.68-52.08)
3.8252 1019 249 986Reynolds et al,49 2020 0.97 (0.79-1.19)
3.7130 413 254 953Richardson et al,50 2020 1.26 (0.98-1.63)
0.62 21 3 18Matsuzawa et al,44 2020 0.53 (0.08-3.56)
0.20 17 1 25Meng et al,45 2020 0.47 (0.02-12.14)
1.54 41 63 241Pan et al,48 2020 0.31 (0.10-0.89)
0.77 45 2 17Sardu et al,52 2020 1.38 (0.26-7.42)
1.331 74 4 39Selcuk et al,5 2020 6.31 (2.03-19.58)
1.27 104 5 52Senkal  et al,53 2020 0.68 (0.20-2.25)
0.30 31 11 69Tan et al,55 2020 0.08 (0.00-1.42)
1.911 40 21 61Xu et al,58 2020 0.72 (0.30-1.73)
0.82 43 11 83Yang et al,59 2020 0.32 (0.07-1.51)
Heterogeneity: Τ2 = 0.17; χ2 = 62.14; df = 25; P <.001; I 2 = 60.0% 
0.7Zhou et al,8 2020 2 15 5 21 0.49 (0.08-2.97)
2.2Zhang et al,61 2020 9 188 51 940 0.88 (0.42-1.81)
39.9
100
Subtotal 692 3890 1016 5934 0.70 (0.54-0.91)
5560 26 093 11 778 72 892 1.11 (0.95-1.31) 
Test for overall effect: z = 2.70; P =.007
Total
Heterogeneity: Τ2 = 0.17; χ2 = 330.29; df = 47; P <.001; I 2 = 86.0% 
Test for overall effect: z = 1.29; P =.20
Test for subgroup differences: χ2 = 22.28; df = 1; P <.001; I 2 = 95.5% 
Subgroup analysis of mortality and severe adverse events in 48 studies of patients who did and did not receive ACEIs or ARBs. A total of 22 studies included a mixed subgroup (a
sample population with multiple mixed comorbidities), and 26 studies included a hypertension subgroup (a sample population with hypertension). Diamonds represent 95% CIs for
subtotal and total ORs. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; and OR, odds ratio.
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The potential mechanisms underlying the beneficial consequences of ACEIs/ARBs remain
unknown. Our results suggest that these benefits are not solely associated with better blood
pressure control, as patients receiving antihypertensive medications that were not ACEIs/ARBs had
comparably inferior clinical outcomes in the adjusted subgroup analysis. Concerns about
upregulation of angiotensin-converting enzyme 2 receptors with the receipt of RAAS inhibitors,
which are derived from inconsistent results in studies with small samples,68,69 have been challenged
by reports of deactivation of RAAS61 with chronic receipt of ACEIs/ARBs. Such downregulation may
limit the inflammatory process, reducing acute lung injury among patients with COVID-19.49
Nevertheless, the findings of the present meta-analysis are consistent with those of national
and international scientific experts,70-72 who recommend continuation of ACEIs/ARBs unless they
are clinically contraindicated. This meta-analysis also indicated that, after adjustment for case mix,
patients with hypertension and COVID-19 who received ACEIs/ARBs were 0.55 times as likely to
experience a severe AE than those who did not receive ACEIs/ARBs, with a similar extent of benefit
observed in the combined hypertension and mixed comorbidities subgroups. Although our study
clarifies the association between RAAS inhibitors and mortality among patients with COVID-19,
future randomized clinical trials are warranted to establish causality.
Figure 4. Subgroup Analysis of Adjusted Mortality and Severe Adverse Events Among Patients













3.2–0.8675 0.5605Conversano et al,19 2020 0.42 (0.14-1.26)
6.1–0.1393 0.2725Bravi et al,7 2020 0.87 (0.51-1.48)
5.8–1.3093 0.2999Chen et al,23 2020 0.27 (0.15-0.49)
2.0–1.9661 0.7860Chen et al,24 2020 0.14 (0.03-0.65)
2.9–0.5798 0.6082Felice et al,9 2020 0.56 (0.17-1.84)
3.0–0.1625 0.5851Gao et al,28 2020 0.85 (0.27-2.68)
1.1–1.0217 1.1211Matsuzawa et al,44 2020 0.36 (0.04-3.24)
2.91.2975 0.6087Selcuk et al,5 2020 3.66 (1.11-12.07)
4.1–0.2485 0.4546Xu et al,58 2020 0.78 (0.32-1.90)
4.2–0.6539 0.4389Yuan et al,60 2020 0.52 (0.22-1.23)
4.4–0.8916 0.4200Zhang et al,61 2020 0.41 (0.18-0.93)
0.8–1.9661 1.3465Zhou et al8 2020 0.14 (0.01-1.96)
Heterogeneity: Τ2 = 0.28; χ2 = 24.24; df = 11; P =.01; I 2 = 55.0% 
40.6Subtotal NA NA 0.55 (0.36-0.85)
Test for overall effect: z = 2.69; P =.007
Mixed subgroup
1.1–1.2379 1.1575Bae et al,20 2020 0.29 (0.03-2.80)
7.6–0.4620 0.1495Bean et al,21 2020 0.63 (0.47-0.84)
8.0–0.1985 0.1107Fosbol et al,27 2020 0.82 (0.66-1.02)
3.3–0.2485 0.5413Gormez et al,29 2020 0.78 (0.27-2.25)
6.4–0.1278 0.2492Jung et al,36 2020 0.88 (0.54-1.43)
6.20.5481 0.2696Liabeuf et al,40 2020 1.73 (1.02-2.93)
2.6–0.4780 0.6602Lopez-Otero et al,42 2020 0.62 (0.17-2.26)
4.9–0.7765 0.3763Mostaza et al,46 2020 0.46 (0.22-0.96)
5.7–0.1985 0.3062Shah et al,54 2020 0.82 (0.45-1.49)
6.8–0.9943 0.2209Zhou et al,10 2020 0.37 (0.24-0.57)
6.80.4947 0.2179Mehta et al,6 2020 1.64 (1.07-2.51)
Heterogeneity: Τ2 = 0.15; χ2 = 37.04; df = 10; P <.001; I 2 = 73.0% 
59.4
100
Subtotal NA NA 0.79 (0.59-1.07)
NA NA 0.68 (0.53-0.88)
Test for overall effect: z = 1.54; P =.12
Total
Heterogeneity: Τ2 = 0.19; χ2 = 66.95; df = 22; P <.001; I 2 = 67.0% 
Test for overall effect: z = 3.01; P =.003
Test for subgroup differences: χ2 = 1.78; df = 1; P =.18; I 2 = 43.9% 
Subgroup analysis of adjusted mortality and severe
adverse events in 23 studies of patients who did and
did not receive ACEIs or ARBs. A total of 11 studies
included a mixed subgroup (sample population with
multiple mixed comorbidities), and 12 studies included
a hypertension subgroup (defined as a sample
population with hypertension). Diamonds represent
95% CIs for subtotal and total ORs. ACEI indicates
angiotensin-converting enzyme inhibitor; ARB,
angiotensin receptor blocker; and OR, odds ratio.
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Limitations
This study has limitations. First, the study was limited by the insufficient data and varying study designs
available, which did not allow for comparison of these analyses with a control group. The meta-analysis
was primarily composed of observational studies because studies with higher levels of evidence, such
as randomized clinical trials, were lacking. Second, the meta-analysis indicated substantial unadjusted
and moderate adjusted levels of heterogeneity, which is typical in observational studies that include
patients with diverse characteristics across large geographic regions. Nevertheless, measures were
taken to maintain a homogeneous study population. A standard definition for severe AEs was used, and
patients with unconfirmed COVID-19 were excluded. Third, we did not define the criteria for chronic
receipt of ACEIs/ARBs. Insufficient description was available to distinguish between study participants,
which is likely a factor associated with the increased heterogeneity observed in the study. With these
limitations in mind, there were no data indicating that the receipt of ACEIs/ARBs was associated with
harm if patients subsequently contracted COVID-19; on the contrary, ACEIs/ARBs may be associated
with substantial protective benefits.
Conclusions
This comprehensive systematic review and meta-analysis of 52 studies indicated no higher risks of
multivariable-adjusted mortality or severe AEs associated with the receipt of ACEIs/ARBs, which is
consistent with recommendations for the continuation of these medications among patients for
whom they are prescribed for the treatment of any condition. On the contrary, ACEIs and ARBs may
be associated with protective benefits, particularly among patients with hypertension. Future
randomized clinical trials are warranted to confirm the beneficial implications of these medications.
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